If you liked this article you might like

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer
Look for Clovis Oncology to Resume Its Advance
Goldman Sachs Raises Clovis Oncology Price Target to $75
6 Stocks Trending Up With Major Volume